

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GLUGAGON-LIKE	:	CIVIL ACTION
PEPTIDE-1 RECEPTOR AGONISTS	:	
(GLP-1 RAS) PRODUCTS	:	
LIABILITY LITIGATION	:	
<hr/>		
THIS DOCUMENT RELATES TO:	:	MDL No. 3094
	:	24-md-3094
<i>ALL ACTIONS/ALL CASES</i>	:	
<hr/>		

ORDER

AND NOW, this 18th day of April, 2024, upon consideration of the Motions for *Pro Hac Vice* Admission (Doc. Nos. 84, 88, 89, 97), it is **ORDERED** that the Motions (Doc. Nos. 84, 88, 89, 97) are **GRANTED** and the following counsel are admitted *pro hac vice* for this Litigation, as follows:

1. Dr. Lucas Przymusinski, Esquire is admitted *pro hac vice* as counsel for the Novo Nordisk Defendants.
2. Jonathan M. Redgrave, Esquire is admitted *pro hac vice* as counsel for Defendant Eli Lilly and Co.
3. Erica Zolner, Esquire is admitted *pro hac vice* as counsel for Defendant Eli Lilly and Co.
4. Anne Salomon, Esquire is admitted *pro hac vice* as counsel for Defendant Eli Lilly and Co.

Counsel shall (i) familiarize and comport themselves in accordance with the Pennsylvania Rules of Professional Conduct and the rules of this Court, and (ii) presenting counsel shall continue to have responsibility for this matter during its pendency before the Court. Pursuant to this Order,

the above-named counsel shall be permitted to participate in all aspects of the instant litigation on behalf of their clients.¹

BY THE COURT:

s/ Gene E.K. Pratter
GENE E.K. PRATTER
UNITED STATES DISTRICT JUDGE

¹ Counsel must request access to ECF through a PACER account. Information about this process can be found on the Court's website by using the following link: <https://www.paed.uscourts.gov/nextgen-cmecf>.